Free Publications

Search for all returned 6 results

Reducing Bone Marrow Transplant Complications

Smita Bhatia is a pediatric oncologist with a strong interest in cancer outcomes at the University of Alabama at Birmingham. She has received several grant awards from The Leukemia & Lymphoma Society (LLS) during her career. Recently it was announced that her Translational Research Program funding would be renewed for a study about preventing long-term health complications in bone marrow transplant survivors.   In the simplest of terms, what is your research project about? ...

Read more

Another Option Available for Multiple Myeloma Patients

Just on the heels of two approvals last week, the FDA today approved a third therapy to treat patients with multiple myeloma. Elotuzumab (Emplicity ™) is approved for use in combination with another drug, lenalidomide (Revlimid ®) for patients who have failed previous therapies. The dizzying rate at which new therapies have come online for multiple myeloma has created quite a bit of buzz, just ahead of the annual American Society of Hematology Meeting kicking off in Orlando this weeke ...

Read more

Heart Disease in Lymphoma Survivors

  Matthew Matasar is a hematology and oncology specialist at Memorial Sloan-Kettering Cancer Center in New York City. He has a Translational Research Program grant through The Leukemia & Lymphoma Society and is investigating which Hodgkin lymphoma survivors are at greater risk for developing heart disease after receiving radiation therapy to the chest and what diagnostic tests are best.   What kind of research do you do? There’s been a lot of ...

Read more

Achieving the Impossible: What’s ahead in 2018?

We’ve just concluded one of the most historic years on record in terms of new therapy approvals for blood cancers. In all, the U.S. Food and Drug Administration (FDA) approved 18 therapies to treat patients with blood cancers, including some entirely new agents and some new uses for already approved drugs. Among these approvals were the first new therapies – four to be precise – for acute myeloid leukemia (AML) after a 40-year drought in treatment advances for this deadly blood ...

Read more

Targeting AML

  Not for lack of trying, we’ve seen very little progress over the past 40 years in treating acute myeloid leukemia (AML), an aggressive and deadly blood cancer. But we’re finally starting to see the needle move and The Leukemia & Lymphoma Society (LLS) is playing a leading role in going on the offensive against the disease. ...

Read more

Pages